Ironwood Pharmaceuticals (IRWD) : Traders are bullish on Ironwood Pharmaceuticals (IRWD) as it has outperformed the S&P 500 by a wide margin of 12.8% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.93%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.52% in the last 1 week, and is up 10.52% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 8.29% and the 50-Day Moving Average is 9.22%.The 200 Day SMA reached 28.38% Ironwood Pharmaceuticals, Inc. is up 18.88% in the last 3-month period. Year-to-Date the stock performance stands at 28.73%.
Ironwood Pharmaceuticals (IRWD) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $24 and the lowest price target forecast is $10. The average forecast of all the analysts is $14.86 and the expected standard deviation is $4.6.
Company shares have received an average consensus rating of Hold for the current week Ironwood Pharmaceuticals (NASDAQ:IRWD): stock was range-bound between the intraday low of $14.89 and the intraday high of $15.18 after having opened at $15.06 on Fridays session. The stock finally closed in the red at $15.06, a loss of -0.86%. The stock remained in the red for the whole trading day. The total traded volume was 1,154,165 shares. The stock failed to cross $15.18 in Fridays trading. The stocks closing price on Thursday was $14.92.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.